You are here

Stabilization of Therapeutic Peptides by Non-Perturbative Chemical Modification

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41DK103548-01
Agency Tracking Number: R41DK103548
Amount: $225,000.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NIDDK
Solicitation Number: PA13-235
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
SOMERVILLE, MA 02144-1215
United States
DUNS: 78757935
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (617) 627-5651
Business Contact
Phone: (617) 564-3586
Research Institution
TUFTS UNIVERSITY 20 Professors Row
MEDFORD, MA 02155-5807
United States

 () -
 Nonprofit College or University

DESCRIPTION (provided by applicant): Type 2 diabetes is a particularly debilitating disease and is endemic for a large proportion of the world's population. The unmet challenges in disease management are the lack of long-term efficacy in reducing hyperglycemia and the inability to stop progression. Glucagon-like peptide-1 (GLP-1), a natural gut hormone, provides a platform for therapeutics to combat the disease. Peptides in general have potent and selective biological activities, making them highly desirable as therapeutics, but a major obstacle to more widespread use in medicine is limited proteolytic stability. The high potency of GLP-1 itself is nullified by a half-life of less than 2 min after injection. Our laboratory has been developing GLP 1 analogswith enhanced proteolytic stability for several years: we have now discovered that a simple N-terminal modification, designed to deliver large stability enhancements, preserves binding and activity of GLP-1 in cell- based assays. Historically, gains i

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government